基于血清药物化学与网络药理学的通塞脉片抗动脉粥样硬化质量评价及Q-标志物发现
本研究采用血清药物化学与网络药理学相结合的策略,筛选通塞脉片(TSMT)抗动脉粥样硬化(AS)的潜在活性成分及质量控制标志物。从TSMT中鉴定出164个成分,血清中检测到29个原型化合物,预测34个蛋白靶点和151条通路参与抗AS机制。筛选出5个潜在活性成分(阿魏酸、甘草苷、洋川芎内酯I、木犀草素、甘草酸),并建立多成分含量测定与HPLC指纹图谱用于9批TSMT样品的质量评价。
要点
- 通塞脉片血清中29个原型成分可能通过调控脂质、剪切应力及抗炎等通路发挥抗AS作用。
- 阿魏酸、甘草苷、洋川芎内酯I、木犀草素、甘草酸可作为通塞脉片的质量控制标志物。
- 建立的HPLC指纹图谱与多成分含量测定法可用于通塞脉片批次质量评价。
核心结论
- 血清药物化学与网络药理学结合可筛选通塞脉片抗AS的潜在机制与化学质量标志物。
- 阿魏酸、甘草苷、洋川芎内酯I、木犀草素、甘草酸可作为通塞脉片质量控制的关键标志物。
研究设计与样本
- 小鼠口服通塞脉片后,采用UPLC-Q-Exactive Orbitrap/MS分析血清中吸收成分。
- 基于血清原型成分构建成分-靶点-疾病网络,预测抗AS机制并筛选QC标志物。
- 对9批通塞脉片样品进行多成分含量测定和HPLC指纹图谱质量评价。
主要发现
- 通塞脉片中共鉴定出164个成分,小鼠血清中发现29个原型化合物。
- 预测到34个与AS相关的蛋白靶点和151条通路,涉及脂质调节、剪切应力和抗炎等协同调控。
- 筛选出5个潜在活性成分:阿魏酸、甘草苷、洋川芎内酯I、木犀草素、甘草酸。
关键数值与推荐
- 阿魏酸含量不低于1.2798 mg/g,甘草苷不低于0.4716 mg/g,洋川芎内酯I不低于0.5419 mg/g,木犀草素不低于0.1349 mg/g,甘草酸不低于4.0386 mg/g。
临床怎么用
- 可将5个成分作为通塞脉片质量控制的标志物,用于批次质量评价。
- 血清药物化学与网络药理学策略可为中药复方质量标志物发现提供参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The limited therapeutic outcomes of atherosclerosis (AS) have allowed, traditional Chinese medicine has been well established as an alternative approach in ameliorating AS and associated clinical syndromes. Clinically, Tongsaimai tablet (TSMT), a commercial Chinese patent medicine approved by CFDA, shows an obvious therapeutic effect on AS treatment. However, its effective mechanism and quality control still need thorough and urgent exploration. METHODS: The mice were orally administered with TSMT and their serum was investigated for the absorbed compounds using serum pharmacochemistry via the UPLC-Q-Exactive Orbitrap/MS analysis was employed to investigate these absorbed compounds in serum of mice orally administrated with TSMT. Based on these absorbed prototype compounds in serum derived from TSMT, a component-target-disease network was constructed using network pharmacology strategy, which elucidated the potential bioactive components, effective targets, and molecular mechanisms of TSMT against AS. Further, the screened compounds from the component-target network were utilized as the quality control (QC) markers, determining multi-component content determination and HPLC fingerprint to assess quality of nine batches of TSMT samples. RESULTS: A total of 164 individual components were identified in TSMT. Among them, 29 prototype compounds were found in serum of mice administrated with TSMT. Based on these candidate prototype components, 34 protein targets and 151 pathways related to AS were predicted, and they might significantly exhibit potential anti-AS mechanisms via synergistic regulations of lipid regulation, shear stress, and anti-inflammation, etc. Five potentially bioactive ingredients in TSMT, including Ferulic acid, Liquiritin, Senkyunolide I, Luteolin and Glycyrrhizic acid in quantity not less than 1.2798, 0.4716, 0.5419, 0.1349, 4.0386 mg/g, respectively, screened from the component-target-pathway network. Thereby, these indicated that these five compounds of TMST which played vital roles in the attenuation of AS could serve as crucial marker compounds for quality control. CONCLUSIONS: Overall, based on the combination of serum pharmacochemistry and network pharmacology, the present study firstly provided a useful strategy to establish a quality assessment approach for TSMT by screening out the potential anti-AS mechanisms and chemical quality markers.
引用
- Cheng Y, Xiao M, Chen J, et al. Quality assessment and Q-markers discovery of Tongsaimai tablet by integrating serum pharmacochemistry and network pharmacology for anti-atherosclerosis benefit. Chin Med. 2022. PMID: 36056398. doi:10.1186/s13020-022-00658-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。